Arhive

"The Present", documentar cu Dimitri Poffé, este acum disponibil pe Youtube

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore […]

PTC Therapeutics încheie un acord global de licență și colaborare cu Novartis pentru programul PTC518 pentru boala Huntington

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics încetează dezvoltarea dalzanemdor în HD

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Puterea parteneriatului. Elveția și China dau un exemplu.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Lives Lives - o nouă carte care prezintă poveștile oamenilor afectați de HD din întreaga lume

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics anunță o finanțare de 35 de milioane de lire sterline pentru a promova un nou medicament destinat inhibării expansiunii somatice în boala Huntington

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

Congresul MENA pentru bolile rare

Congresul HDYO

FDA acordă desemnarea Fast Track pentru programul PTC518 pentru boala Huntington

PTC518 este un medicament oral care reduce producția proteinei Huntingtin mutante care cauzează progresia bolii. Programele cu desemnare Fast Track pot beneficia de interacțiuni timpurii cu FDA și pot fi [...]

Pridopidina de la Prilenia pentru boala Huntington a fost acceptată pentru revizuirea autorizației europene de introducere pe piață

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]